Page 8 - Key Challenges News Today

VivaVision Biotech has reported positive topline data from a Phase II clinical trial of VVN001 in dry eye disease patients.

BrainStorm is generating stem cells to test its ALS drug in a genetic subpopulation after missing the mark in a Phase III trial.

The Anywhere Workplace: Is Hybrid Work the Next Normal?

Experts were less keen on variant-specific vaccines versus Covid-19/flu combo due to lack of practical value, despite scientific rationale.

We've assembled a full guide on Super Nintendo World, so you can learn everything there is to know about the amazing Universal Studios area!

Equillium has commenced the Phase III EQUATOR clinical trial of itolizumab to treat acute graft-versus-host disease (aGVHD) patients.

"I think it’s a terrible idea if the FDA would keep processing Russia entities’ pitches to enter the US market.”

Maze has commenced participant dosing in its Phase I clinical trial of oral glycogen synthase (GYS1) inhibitor, MZE001, to treat Pompe diseas

Pardes Biosciences has reported interim results from the Phase I trial of its oral antiviral drug, PBI-0451, in healthy adult subjects.

IGM Biosciences has announced the progression of its antibody, IGM-6268, into two clinical trials to treat and prevent Covid-19.